ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0550

Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Abstract Number: 1405

In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
Abstract Number: 0265

In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
Abstract Number: 1408

In RA Patients Without Prevalent CVD, Incident CVD Is Only Associated with Traditional Risk Factors: A 20-year Follow up in the CARRÉ Cohort Study
Abstract Number: 0394

In Radiographic Axial Spondyloarthritis Spinal Mobility Measures Correlate Well with the Whole Spine CT Syndesmophyte Score (CTSS)
Abstract Number: 1674

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth
Abstract Number: 1737

In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Abstract Number: 1214

In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis
Abstract Number: 1391

Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1422

Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Abstract Number: 0451

Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
Abstract Number: 1449

Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Abstract Number: 0804

Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Abstract Number: 0372

Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Abstract Number: 0886

Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].